natgillin/translations-raw huggingface dataset:
Musculoskeletal and connective tissue disorders muscle and joint pain
Bolezni mišično skeletnega sistema in bolečine v mišicah in sklepih vezivnega tkiva Čutila motnje okusa in vida.
Warfarin
Teofilin
The lansoprazole dose should therefore be taken at least an hour prior or after.
Antacidi in sukralfat lahko zmanjšajo biološko uporabnost lansoprazola, zato je treba odmerek lansoprazola vzeti vsaj eno uro prej ali pozneje.
Effect on gastric acid secretion: Lansoprazole is a specific inhibitor of the parietal cell proton pump.
Lansoprazol je specifični zaviralec protonske črpalke parietalnih celic.
H. pylori eradication rate of between 80 and 90%.
Za kombinacijo lansoprazola z antibiotiki v dvotirnem ali trotirnem zdravljenju je bila dokazana stopnja eradikacije H. pylori v razponu med 80 in 90 %.
Special Precautions for Storage Do not store above 25ºC.
Zdravilo shranjujte pri temperaturi do 25 °C.
[To be completed nationally] 4.
[Podatke je treba dopolniti v posameznih državah] 6.2 Inkompatibilnosti
also contributes to the metabolism.
K presnovi prispeva tudi encim
Titanium dioxide (E 171) In addition for Lansoprazole 15 mg: Quinoline yellow (E 104) [To be completed nationally] 6.2.
Pri zdravilu Lansoprazol 15 mg tudi: Kinolinsko rumeno (E 104)
MARKETING AUTHORISATION HOLDER [To be completed nationally]
IMETNIK DOVOLJENJA ZA PROMET Z ZDRAVILOM [Podatke je treba dopolniti v posameznih državah]
Pharmacokinetic Properties
5.2 Farmakokinetične lastnosti
Posology and Method of Administration
4.2 Odmerjanje in način uporabe
methacrylic acid ethyl acrylate copolymer, 1:1, dispersion 30 % Capsule shell:
Titanov dioksid (E 171) kopolimer metilakrilne kisline in etilakrilata (1:1, 30-odstotna disperzija)
ATPase of the parietal cells in the stomach.
ATPaze parietalnih celic želodca zavira končno stopnjo tvorbe želodčne kisline.
Due to the lack of data in patients with severely impaired hepatic function, these patients should not be treated with lansoprazole (see section 4.4 “Special warnings and precautions for use”).
Zaradi pomanjkanja podatkov, bolnikov s hudo okvaro delovanja jeter ne smemo zdraviti z lansoprazolom
Lansoprazole 30 mg combined with amoxicillin 1g, clarithromycin 250 or 500 mg, or metronidazole 400
klaritromicinom 250 ali 500 mg ali metronidazolom 400 mg dvakrat dnevno dokazali 71- do 94
Caution and increased monitoring frequency is advised when initiating or ending lansoprazole co treatment in patients treated with warfarin.
Varfarin Ob začetku in koncu sočasnega zdravljenja z lansoprazolom in varfarinom se priporočata previdnost in pogostejši nadzor.
mg of lansoprazole have been administered in trials without significant undesirable effects.
V preskušanjih so brez bistvenih neželenih učinkov uporabili odmerke do 180 mg lansoprazola dnevno.
Treatment of duodenal ulcer: The recommended dose is 30 mg once daily for 2 weeks.
Zollinger-Ellisonov sindrom: Priporočeni začetni odmerek je 60 mg enkrat dnevno.
mg twice daily was associated with eradication rates ranging from 71 to 94%, and ulcer healing rates were generally >80% in well designed studies.
odstotno stopnjo eradikacije ter običajno >80-odstotno stopnjo zaceljenja razjede.
It inhibits the final stage of gastric acid formation by inhibiting the activity of H +/K
Z zaviranjem aktivnosti H
glossitis, candidiasis of oesophagus, pancreatitis colitis, stomatitis and black tongue.
glositis, kandidiaza ezofagusa, pankreatitis kolitis,
Undesirable effects for possible symptoms of lansoprazole overdose.
Možni simptomi prevelikega odmerjanja lansoprazola so v poglavju 4.8 Neželeni učinki.
Holder
Zaviralec
List of the names, pharmaceutical forms, strengths of the medicinal products, routes of administration, and marketing authorisation holders in the Member States
Seznam imen, farmacevtskih oblik, jakosti zdravila, poti uporabe zdravila, imetnikov dovoljenja za promet z zdravilom v državah članicah
Nebido parenteral use
Nebido parenteralna uporaba
Eli Lilly Norge AS P.B.
Norveška Eli Lilly Norge AS P.B.
Ferring Magyarország Gyógyszerkereskedelmi Kft. Tomori u. 34.
Madžarska Ferring Magyarország Gyógyszerkereskedelmi Kft. Tomori u. 34.
Agovirin depot suspension for injection
Agovirin depot suspenzija za injiciranje
Ferring PortuguesaProdutos Farmacêuticos, Sociedade Unipessoal, Lda.
Portugalska Ferring PortuguesaProdutos Farmacêuticos, Sociedade Unipessoal, Lda.
Pierre Fabre Médicament Portugal, Lda.
Portugalska Pierre Fabre Médicament Portugal, Lda.
capsules oral use
kapsula peroralna uporaba
Organon (Ireland) Limited PO Box 2857, Drynam Road, Swords Co. Dublin Ireland testosterone undecanoate Restandol Testocaps 40 mg capsules, soft oral use
Organon (Ireland) Limited PO Box 2857, Drynam Road, Swords Co. Dublin Ireland testosterone undecanoate Restandol Testocaps 40 mg kapsula, mehka peroralna uporaba
capsule, soft oral use
kapsula, mehka peroralna uporaba
Hertford Road Hoddesdon Hertfordshire EN11 9BU United Kingdom testosterone undecanoate Restandol 40mg capsule oral use
Hertford Road Hoddesdon Hertfordshire EN11 9BU United Kingdom testosterone undecanoate Restandol 40mg kapsula peroralna uporaba
BAYER SANTE 220, avenue de la Recherche 59120 Loos France testosterone undecanoate NEBIDO 1000 mg/4 ml, solution injectable
BAYER SANTE 220, avenue de la Recherche 59120 Loos France testosterone undecanoate NEBIDO 1000 mg/4 ml, solution injectable raztopina
Aspen Pharma Trading Limited.3016 Lake Drive.
Portugalska Aspen Pharma Trading Limited.3016 Lake Drive.
Nebido 250 mg/ml oldatos injekció intramuscular injection
Nebido 250 mg/ml oldatos injekció intramuskularna injekcija
AGOVIRIN DEPOT 5 mg/2 ml suspension for injection
AGOVIRIN DEPOT 5 mg/2 ml suspenzija za injiciranje
92400 Courbevoie France testosterone undecanoate PANTESTONE 40 mg, capsule molle capsule, soft oral use
92400 Courbevoie France testosterone undecanoate PANTESTONE 40 mg, capsule molle kapsula, mehka peroralna uporaba
22,5 mg/patch patch
22,5 mg/patch obliž
ANDROTARDYL 250 mg/1 ml, solution injectable intramusculaire solution
ANDROTARDYL 250 mg/1 ml, solution injectable intramusculaire raztopina
Axiron 30mg/1,5ml Lösung zur Anwendung auf der Haut solution
Axiron 30mg/1,5ml Lösung zur Anwendung auf der Haut raztopina
Axiron cutaneous solution
Axiron dermalna raztopina
Andriol Testocaps 40 mg - Kapseln capsule, soft oral use
Andriol Testocaps 40 mg - Kapseln kapsula, mehka peroralna uporaba
Andriol Testocaps, 40 mg capsules capsule, soft oral use
Andriol Testocaps, 40 mg capsules kapsula, mehka peroralna uporaba
30 mg/patch patch
30 mg/patch obliž
Sweden Laboratoires Besins International
Madžarska Laboratoires Besins International
Germany Laboratoires Besins international
Romunija LABORATOIRES BESINS INTERNATIONAL
15 mg/patch patch
15 mg/patch obliž
2,5 mg/25 mg/ ml suspension for injection
2,5 mg/25 mg/ ml suspenzija za injiciranje
25 mg/ml 2,5 mg/ml suspension for injection
25 mg/ml 2,5 mg/ml suspenzija za injiciranje
The Netherlands testosterone undecanoate Andriol capsule, soft oral use
The Netherlands testosterone undecanoate Andriol kapsula, mehka peroralna uporaba
Lithuania Bayer Pharma AG Mullerstrasse 178
Madžarska Bayer Pharma AG Müllerstrasse 178
The Netherlands testosterone undecanoate Testocaps capsule, soft oral use
The Netherlands testosterone undecanoate Testocaps kapsula, mehka peroralna uporaba
Testogel cutaneous transdermal use
Testogel dermalna transdermalna uporaba
Axxeron transdermal spray, solution
Axxeron transdermalno pršilo, raztopina
1000 mg/dose solution for injection
1000 mg/dose raztopina za injiciranje
Testim cutaneous and transdermal preparations
Testim dermalna in transdermalna uporaba
Lithuania N.V. ORGANON P.O.
Romunija N.V.
5340 BH Oss The Netherlands testosterone undecanoate Andriol Testocaps 40 mg lágy kapszula capsule, soft oral use
The Netherlands testosterone undecanoate Andriol Testocaps 40 mg lágy kapszula kapsula, mehka peroralna uporaba
Ireland testosterone undecanoate Nebido 1000 mg/4ml, solution for injection intramuscular
Ireland testosterone undecanoate Nebido 1000 mg/4ml, solution for injection intramuskularna
N.V. Organon Kloosterstraat 6 5349 AB Oss The Netherlands testosterone undecanoate Andriol capsule, soft oral use
Organon Kloosterstraat 6 5349 AB Oss The Netherlands testosterone undecanoate Andriol kapsula, mehka peroralna uporaba
2,4mg/24h, transdermales Pflaster transdermal patch
2,4mg/24h, transdermales Pflaster transdermalni obliž
Axxeron cutaneous solution
Axxeron dermalna raztopina
N.V. Organon 6 Kloosterstraat 5340 BH Oss The Netherlands testosterone undecanoate Undestor capsule, soft oral use
Organon 6 Kloosterstraat 5340 BH Oss The Netherlands testosterone undecanoate Undestor kapsula, mehka peroralna uporaba
Testim cutaneous transdermal use
Testim dermalna transdermalna uporaba
1,8mg/24h, transdermales Pflaster transdermal patch
1,8mg/24h, transdermales Pflaster transdermalni obliž
Testogel gel in sachet cutaneous and transdermal preparations
Testogel gel v vrečici dermalna in transdermalna uporaba
Germany testosterone undecanoate Andriol Testocaps capsule oral use
85540 Haar Germany testosterone undecanoate Andriol Testocaps kapsula peroralna uporaba
1,2mg/24h, transdermales Pflaster transdermal patch
1,2mg/24h, transdermales Pflaster transdermalni obliž
Denmark Bayer Pharma AG Müllerstrasse 170-178
Norveška Bayer Pharma AG, Müllerstrasse 178
Tostrex cutaneous and transdermal preparations
Tostrex dermalna in transdermalna uporaba
ProStrakan Limited Galabank Business Park Galashiels, TD1 1QH United Kingdom
Madžarska ProStrakan Limited Galabank Business Park Galashiels, TD1 1QH United Kingdom
Bayer Pharma AG Müllerstrasse 178 13353 Berlin Germany testosterone undecanoate Nebido solution for injection intramuscular
Bayer Pharma AG Müllerstrasse 178 13353 Berlin Germany testosterone undecanoate Nebido raztopina za intramuskularno injiciranje
N.V. ORGANON Kloosterstraat 6 5349 AB Oss The Netherlands testosterone undecanoate Undestor Testocaps 40 mg capsule oral use
ORGANON Kloosterstraat 6 5349 AB Oss The Netherlands testosterone undecanoate Undestor Testocaps 40 mg kapsula peroralna uporaba
Besins International, S.A. 5, Rue du Bourg l'Abbé F-75003 Paris France
Portugalska Besins International, S.A. 5, Rue du Bourg l'Abbé F-75003 Paris
2.4 mg/24 h transdermal patch
2.4 mg/24 h transdermalni obliž
N.V. Organon Kloosterstraat 6 5349 AB Oss The Netherlands testosterone undecanoate Restandol Testocaps 40 mg capsules, soft oral use
Organon Kloosterstraat 6 5349 AB Oss The Netherlands testosterone undecanoate Restandol Testocaps 40 mg kapsula, mehka peroralna uporaba
50 mg/dose gel in sachetdose
50 mg/dose gel v odmerni vrečici
1.2 mg/24 h transdermal patch
1.2 mg/24 h transdermalni obliž
1.8 mg/24 h transdermal patch
1.8 mg/24 h transdermalni obliž
N.V. Organon Kloosterstraat 6 5349 AB Oss The Netherlands testosterone undecanoate Undestor Testocaps 40 mg capsule, soft oral use
Organon Kloosterstraat 6 5349 AB Oss The Netherlands testosterone undecanoate Undestor Testocaps 40 mg kapsula, mehka peroralna uporaba
1.8 mg/24h transdermal patch
1.8 mg/24h transdermalni obliž
Androgel 50 mg gel in sachet gel in sachet
Androgel 50 mg gel in sachet gel v vrečici
1.2 mg/24h transdermal patch
1.2 mg/24h transdermalni obliž
25 mg/dose gel in sachetdose
25 mg/dose gel v odmerni vrečici
Germany ProStrakan Limited Galabank Business Park TD1 QH Galashiels United Kingdom
Portugalska ProStrakan Limited Galabank Business Park TD1 1QH Galashiels United Kingdom
Androgel 25 mg gel in sachet gel in sachet
Androgel 25 mg gel in sachet gel v vrečici
2.4 mg/24h transdermal patch
2.4 mg/24h transdermalni obliž
Androtop 50 mg gel v blazinici gel in sachet
Androtop 50 mg gel v blazinici gel v vrečici
Androtop 25 mg gel v blazinici gel in sachet
Androtop 25 mg gel v blazinici gel v vrečici
Axiron cutaneous solution cutaneous and transdermal preparations
Axiron dermalna raztopina dermalna in transdermalna uporaba
Fostering transparency, communication and the provision of information
Spodbujanje preglednosti, obveščanja in zagotavljanja informacij
By the end of the year, 29.4 million people in Europe had been vaccinated with one of these products.
Do konca leta se je s temi cepivi cepilo 29,4 milijona ljudi v Evropi.
Consolidating the Agency's international strategy in the light of global challenges
Krepitev mednarodne strategije agencije v luči svetovnih izzivov
Improving the effectiveness and efficiency of the Agency's core activities
Izboljšanje uspešnosti in učinkovitosti glavnih dejavnosti agencije
The CAT is a multidisciplinary committee made up of some of the best experts in the field.
CAT je večdisciplinaren odbor, ki ga sestavljajo nekateri najboljši strokovnjaki na svojem področju.
Thirtytwo competent authorities are now registered, with a total of 150 different users.
Zdaj je registriranih dvaintrideset pristojnih organov s skupno 150 posameznimi uporabniki.
Existing regulatory guidance documents were also updated, to take account of the new rules.
Posodobljene so bile tudi obstoječe regulativne smernice, ki tako odražajo nova pravila.
There are also 111 organisations registered (marketing-authorisation holders and third parties), with a total of 176 different users.
Registriranih je tudi 111 organizacij (imetnikov dovoljenj za promet z zdravilom in tretjih strani) s skupno 176 posameznimi uporabniki.
Implementing and operating the Advanced Therapies Regulation and other new legislation
Izvajanje in delovanje uredbe o naprednem zdravljenju in druge nove zakonodaje
Strengthening the European medicines network
Krepitev Evropske mreže zdravil
By the end of the year, the international strategy was included as an important part of the Agency's 'Road map to 2015', adopted by the Agency's Management Board for public consultation.
Konec leta je bila mednarodna strategija vključena kot pomemben del „časovnega načrta agencije do leta 2015“, ki ga je upravni odbor agencije sprejel za javno posvetovanje.
In 2009, the European Medicines Agency delivered very good results across the range of its activities.
V letu 2009 je Evropska agencija za zdravila dosegla zelo dobre rezultate na več področjih svojega delovanja.
All major companies are now registered and operating electronic reporting via EVVet.
Zdaj so registrirane vse poglavitne družbe, ki prek sistema EVVet izvajajo elektronsko poročanje.
Thus, the CHMP was able to give positive recommendations for two pandemic-influenza vaccines (Focetria and Pandemrix) by late September, and for a third one (Celvapan) in early October.
Zato je CHMP lahko dal pozitivno priporočilo dvema cepivoma proti pandemski gripi (Focetria in Pandemrix) konec septembra, v začetku oktobra pa še tretjemu cepivu (Celvapan).
In many areas, the Agency was able to make a significant further contribution to public and animal health in the European Union (EU).
Na več področjih je agencija bistveno prispevala k javnemu zdravju in zdravju živali v Evropski uniji (EU).
The development of the Agency's international strategy started with the appointment of an International Liaison Officer in the beginning of 2009.
Razvoj mednarodne strategije agencije se je začel z imenovanjem mednarodnega uradnika za zvezo na začetku leta 2009.
The Agency also cooperated closely with the European Commission on fostering innovation in the context of the Innovative Medicines Initiative (IMI), the 7th Framework Programme and the European Technology Platform for Global Animal Health.
Agencija je tesno sodelovala tudi z Evropsko komisijo pri spodbujanju inovacij v okviru pobude za inovativna zdravila (IMI), 7. okvirnega programa in evropske tehnološke platforme za globalno zdravstveno varstvo živali.
The European Pharmacovigilance Issues Tracking Tool (EPITT) is now routinely used to support the signal-management process.
Orodje European Pharmacovigilance Issues Tracking Tool (EPITT) se sedaj redno uporablja za podporo postopku obvladovanja signalov.
Highlights from the Agency's annual report 2009
Poudarki letnega poročila za leto 2009
PROTECT is a collaborative European project bringing together 29 public and private partners, which aims to develop innovative methods in pharmacoepidemiology and pharmacovigilance.
PROTECT je evropski projekt, v katerem sodeluje 29 javnih in zasebnih partnerjev, katerih skupni cilj je razviti inovativne metode v farmakoepidemiologiji in farmakovigilanci.
This plan is designed to improve the handling and coordination of any potential crisis involving a medicine in the European medicines system.
Ta načrt je bil zasnovan za izboljšanje obvladovanja in usklajevanja morebitne krize, ki bi zajemala zdravilo v evropskem sistemu zdravil.
The Agency delivered good results on a number of processes and procedures that contribute to the innovation and availability of medicines for human and animal use.
Agencija je dosegla dobre rezultate pri številnih procesih in postopkih, ki prispevajo k inovacijam in razpoložljivosti zdravil za uporabo v humani in veterinarski medicini.
Although the Agency devoted significant time and resources in 2009 to its involvement in managing the unanticipated influenza pandemic, it was still able to achieve very good results in delivering on its ambitious work programme for the year.
Čeprav je agencija v letu 2009 velik del časa in virov namenila sodelovanju pri obvladovanju nepričakovane pandemije gripe, je vseeno dosegla zelo dobre rezultate pri izvedbi ambicioznega delovnega programa za to leto.
The EudraVigilance Support Programme was initiated at the end of January 2009 to assist Member States with their signal-detection and evaluation activities.
Konec januarja 2009 se je začel podporni program EudraVigilance, katerega namen je bil državam članicam olajšati zaznavanje signalov in ocenjevalne aktivnosti.
In early May, the Agency's Committee for Medicinal Products for Human Use (CHMP) recommended that the shelf-life of one of these medicines (Tamiflu) be extended, so that stocks of the medicine that would otherwise need to have been disposed of could continue to be used in the event of a pandemic being declared.
V začetku maja je Odbor za zdravila za uporabo v humani medicini (CHMP) priporočil podaljšanje roka uporabnosti enega od teh zdravil (Tamiflu), da bi bilo zaloge zdravila, ki bi jih bilo sicer treba zavreči, mogoče uporabiti v primeru razglasitve pandemije.
The need for continuous reflection on the Agency's activities in the area of transparency was underlined by the continuing increase in the number of requests received for access to documents and information.
Potrebo pa stalnem odzivanju na dejavnosti agencije na področju preglednosti poudarja stalno povečevanje prejetih zahtevkov za dostop do dokumentov in informacij.
Preparing for the implementation of the Variations Regulation, the Agency provided to the European Commission, at the end of February 2009, draft guidelines on the detailed classification of variations and on the procedure for handling of variations in accordance with the new legislation.
V okviru priprav za izvajanje uredbe o spremembah je agencija konec februarja 2009 Evropski komisiji predložila osnutek smernic o podrobni razvrstitvi sprememb in o postopku za obravnavo sprememb v skladu z novo zakonodajo.
A number of pilot projects fostering international collaboration in the area of inspections were also launched during the year.
Med letom so se začeli številni pilotni projekti, ki pospešujejo mednarodno sodelovanje na področju inšpekcijskih pregledov.
That the EU medicines system was able to deliver an appropriate response to this public-health crisis was further evidence of its robustness and good functioning.
Sistem zdravil v EU se je torej ustrezno odzval na javnozdravstveno krizo, kar je bil še dodaten dokaz njegove trdnosti in dobrega delovanja.
During the year, the Agency continuously monitored the safety data for influenza vaccines and antivirals, to establish and revise, where necessary, their benefit-risk profile.
Med letom je agencija nenehno spremljala varnostne podatke za cepiva proti gripi in protivirusna zdravila, da bi ugotovili in po potrebi popravili profil koristi in tveganj.
In addition, the Agency published, in June 2009, a report on patients', consumers' and healthcare professionals' expectations with regard to information on the benefit-risk evaluation of medicines.
Poleg tega je agencija junija 2009 objavila poročilo o pričakovanjih bolnikov, potrošnikov in zdravstvenega osebja glede informacij o ocenah koristi in tveganj zdravil.
The Agency's sixth scientific committee, the Committee for Advanced Therapies (CAT), was inaugurated in January 2009, in accordance with provisions contained in the new legislation on advanced therapy medicinal products (ATMPs).
Šesti znanstveni odbor pri agenciji, Odbor za napredno zdravljenje (CAT), je bil slovesno ustanovljen januarja leta 2009 v skladu z določbami nove zakonodaje o zdravilih za napredno zdravljenje (ATMP).
When the first reported cases of infection emerged from Mexico, in April, the Agency reacted quickly, working closely with its European and international partners to monitor the situation and develop appropriate measures to deal with the emerging crisis, including meeting with vaccine manufacturers and influenza experts from across the EU to prepare for the development and authorisation of vaccines that could be used to protect people and minimise the spread of the virus.
Ko so aprila poročali o prvih primerih okužbe v Mehiki, se je agencija odzvala hitro ter pričela tesno sodelovati s svojimi evropskimi in mednarodnimi partnerji, da bi spremljali razmere in sprejeli ustrezne ukrepe za obvladovanje porajajoče se krize, vključno s sestanki z izdelovalci cepiv in strokovnjaki za gripo iz celotne EU, ter se pripravili na razvoj in odobritev cepiv, s katerimi bi zaščitili ljudi ter v čim bolj zmanjšali širjenje virusa.
A pilot phase of the EU regulatory system incident-management plan for medicines for human use was launched on 1 June 2009.
Pilotna faza načrta za obvladovanje dogodkov v regulativnem sistemu EU za zdravila za uporabo v humani medicini se je začela 1. junija 2009.
A particular highlight was the introduction, in September 2009, of a range of measures to promote the authorisation of products for minor uses, minor species and limited markets.
Zlasti je izstopala uvedba številnih ukrepov za pospeševanje odobritve zdravil za manjšo uporabo, redkejše živalske vrste in omejene trge septembra leta 2009.
Improving the safety-monitoring of medicines
Izboljšanje spremljanja varnosti zdravil
On the basis of these scientific recommendations, the European Commission granted EU-wide marketing authorisations for all three vaccines, making them available for use by health authorities in the EU Member States as part of their national vaccination programmes.
Na podlagi teh znanstvenih priporočil je Evropska komisija izdala dovoljenja za promet z vsemi tremi cepivi za celotno EU, kar je zdravstvenim organom v državah članicah EU omogočilo njihovo uporabo v okviru svojih nacionalnih cepilnih programov.
However, due to the strength of the network, the Agency was not only able to contribute to the EU-wide response to the pandemic by providing its scientific opinion on H1N1 vaccines and antiviral medicines, it was also able to deliver good results across the range of its activities.
Vendar je lahko zaradi čvrstosti mreže agencija ne le prispevala k odzivu na pandemijo v celotni EU z zagotavljanjem strokovnih mnenj o cepivih ter zdravilih proti virusu H1N1, pač pa dobre rezultate dosegla tudi na vseh svojih področjih.
The public-health issue to which the Agency devoted most attention in 2009 was the outbreak and rapid global spread of the H1N1 influenza ('swine flu') virus.
Javnozdravstvena težava, ki ji je agencija namenila največ pozornosti v letu 2009, je bil izbruh in hitro širjenje virusa gripe H1N1 („prašičje gripe“) po svetu.